Bioxyne achieves a $10 million annual revenue run rate, with Q2 reaching $2.56 million. The TGA GMP audit is completed, and Bioxyne anticipates obtaining its GMP manufacturing license by February 2024. The company launches CanXChange to target the Australian medical cannabis market valued at over $500 million. The article was developed in collaboration with Bioxyne.
Read the full story here
Written by: Special Report
Published on January 29, 2024 at 12:53PM
Source: Stockhead (opens in new tab)